Literature DB >> 28735441

Pathology of Neuroendocrine Tumours of the Female Genital Tract.

Brooke E Howitt1, Paul Kelly2,3, W Glenn McCluggage4,5.   

Abstract

Neuroendocrine tumours are uncommon or rare at all sites in the female genital tract. The 2014 World Health Organisation (WHO) Classification of neuroendocrine tumours of the endometrium, cervix, vagina and vulva has been updated with adoption of the terms low-grade neuroendocrine tumour and high-grade neuroendocrine carcinoma. In the endometrium and cervix, high-grade neoplasms are much more prevalent than low-grade and are more common in the cervix than the corpus. In the ovary, low-grade tumours are more common than high-grade carcinomas and the term carcinoid tumour is still used in WHO 2014. The term ovarian small-cell carcinoma of pulmonary type is included in WHO 2014 for a tumour which in other organs is termed high small-cell neuroendocrine carcinoma. Neuroendocrine tumours at various sites within the female genital tract often occur in association with other neoplasms and more uncommonly in pure form.

Entities:  

Keywords:  Cervix; Endometrium; Immunohistochemistry; Neuroendocrine carcinoma; Neuroendocrine tumour; Ovary; Uterus

Mesh:

Year:  2017        PMID: 28735441     DOI: 10.1007/s11912-017-0617-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  118 in total

1.  Large cell neuroendocrine [corrected] carcinoma of the uterine cervix: a clinicopathologic study of 12 cases.

Authors:  C B Gilks; R H Young; D J Gersell; P B Clement
Journal:  Am J Surg Pathol       Date:  1997-08       Impact factor: 6.394

2.  p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas.

Authors:  Llucia Alos; Sofia Hakim; Ana-Belen Larque; Jorge de la Oliva; Leonardo Rodriguez-Carunchio; Miguel Caballero; Alfons Nadal; Carles Marti; Nuria Guimera; Maria-Teresa Fernandez-Figueras; Wim Quint; Jaume Ordi
Journal:  Virchows Arch       Date:  2016-07-08       Impact factor: 4.064

3.  Malignant transformation of ovarian mature cystic teratoma with a predominant pulmonary type small cell carcinoma component.

Authors:  Hayato Ikota; Kou Kaneko; Sachio Takahashi; Mitsue Kawarai; Yuko Tanaka; Hideaki Yokoo; Yoichi Nakazato
Journal:  Pathol Int       Date:  2012-02-28       Impact factor: 2.534

4.  Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count.

Authors:  Volkan Adsay
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

5.  Large cell neuroendocrine carcinoma with sarcomatous changes of the endometrium: a case report with immunohistochemical studies and molecular genetic study of KIT and PDGFRA.

Authors:  Tadashi Terada
Journal:  Pathol Res Pract       Date:  2010-02-26       Impact factor: 3.250

6.  ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin.

Authors:  Abbas Agaimy; Katharina Erlenbach-Wünsch; Björn Konukiewitz; Anja M Schmitt; Ralf J Rieker; Michael Vieth; Franklin Kiesewetter; Arndt Hartmann; Giuseppe Zamboni; Aurel Perren; Günter Klöppel
Journal:  Mod Pathol       Date:  2013-03-15       Impact factor: 7.842

7.  Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid.

Authors:  S J Robboy; R E Scully
Journal:  Cancer       Date:  1980-11-01       Impact factor: 6.860

Review 8.  Treatment of gastroenteropancreatic neuroendocrine tumors.

Authors:  U Plöckinger; B Wiedenmann
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

9.  Small cell carcinoma of the endometrium with concomitant pelvic inflammatory disease.

Authors:  J Chuang; C C Chu; J L Hwang; W C Cheng
Journal:  Arch Gynecol Obstet       Date:  2002-07       Impact factor: 2.344

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  19 in total

Review 1.  The central role of the pathologist in the management of patients with cervical cancer: ESGO/ESTRO/ESP guidelines.

Authors:  Maria Rosaria Raspollini; Sigurd F Lax; W Glenn McCluggage
Journal:  Virchows Arch       Date:  2018-05-24       Impact factor: 4.064

2.  Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.

Authors:  Deyin Xing; Gang Zheng; John Kenneth Schoolmeester; Zaibo Li; Aparna Pallavajjala; Lisa Haley; Michael G Conner; Russell Vang; Chien-Fu Hung; Tzyy-Choou Wu; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2018-06       Impact factor: 6.394

3.  Dedifferentiated Endometrioid Carcinomas with Neuroendocrine Differentiation: A Clinicopathological and Immunohistochemical Study of Three Cases.

Authors:  Feng Zhou; Xiaofei Zhang; Hao Chen; Wenxin Zheng
Journal:  Cancer Manag Res       Date:  2020-11-13       Impact factor: 3.989

4.  Role of diagnostic laparoscopy in patients with large cell neuroendocrine carcinoma of the ovary with cancerous peritonitis: case report and review of the literature.

Authors:  Hideaki Tsuyoshi; Kenji Yashiro; Shizuka Yamada; Makoto Yamamoto; Toshimichi Onuma; Tetsuji Kurokawa; Yoshio Yoshida
Journal:  J Ovarian Res       Date:  2019-10-15       Impact factor: 4.234

5.  Mixed large and small cell neuroendocrine carcinoma of the endometrium with serous carcinoma: A case report and literature review.

Authors:  Ruijiao Hu; Jiyong Jiang; Guangyao Song; Chenggong Zhu; Liyan Chen; Chenhui Wang; Xiuying Wang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Neuroendocrine Carcinoma of the Uterine Cervix: A Clinicopathologic and Immunohistochemical Study with Focus on Novel Markers (Sst2-Sst5).

Authors:  Frediano Inzani; Angela Santoro; Giuseppe Angelico; Angela Feraco; Saveria Spadola; Damiano Arciuolo; Michele Valente; Angela Carlino; Alessia Piermattei; Giulia Scaglione; Giovanni Scambia; Guido Rindi; Gian Franco Zannoni
Journal:  Cancers (Basel)       Date:  2020-05-12       Impact factor: 6.639

Review 7.  Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.

Authors:  Fulvio Borella; Mario Preti; Luca Bertero; Giammarco Collemi; Isabella Castellano; Paola Cassoni; Stefano Cosma; Andrea Roberto Carosso; Federica Bevilacqua; Niccolò Gallio; Chiara Benedetto; Leonardo Micheletti
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

8.  Retrospective Analysis of Clinicopathological Features and Prognosis of Gynecological Small-Cell Carcinoma.

Authors:  Li Pang; Hui Yang; Yuer Ning; Chunyu Zheng
Journal:  Cancer Manag Res       Date:  2021-06-08       Impact factor: 3.989

9.  A rare case of neuroendocrine carcinoma of the endometrium metastatic to the thyroid.

Authors:  Nancy Zhou; Nicolette Reese; Shah Giashuddin; Margaux J Kanis
Journal:  Gynecol Oncol Rep       Date:  2021-06-25

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.